Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in
Phase III Pivotal Trial Compared to Neostigmine
OSS, the Netherlands, June 11, 2007-Sugammadex - the novel
selective relaxant binding agent (SRBA) being developed by Organon,
the human healthcare business unit of Akzo Nobel - demonstrated in
a Phase III pivotal trial a 9-12 times faster reversal of
neuromuscular blockade as compared to neostigmi...
Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in
Phase III Pivotal Trial as Compared to Neostigmine
OSS, The Netherlands, June 11, 2007 /PRNewswire/ -- Sugammadex -
the novel selective relaxant binding agent (SRBA) being developed
by Organon, the human healthcare business unit of Akzo Nobel -
demonstrated in a Phase III pivotal trial a 9-12 times faster
reversal of neuromuscular blockade as comp...
BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
...r stimulation (deep block), patients were administered either
sugammadex or
neostigmine plus glycopyrrolate, a current reversal regimen.
In the SIGNAL trial, the m...timulation (moderate block) patients were administered
either sugammadex or
neostigmine plus glycopyrrolate. In the AURORA trial,
the median time to reversal of mu...
European Union's CHMP Issues Positive Opinion on Sugammadex
...r stimulation (deep block), patients were
administered either sugammadex or
neostigmine plus glycopyrrolate, the
current standard of care in reversal. SIGNAL clini...timulation (moderate block) patients were administered
either sugammadex or
neostigmine plus glycopyrrolate, the current standard
of care in reversal. AURORA clini...
Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia
...rom profound neuromuscular blockade as
compared to
neostigmine in the Phase III pivotal Signal trial.(1) In a
sec...omized to receive either sugammadex (4.0 mg/kg)
or
neostigmine (70 micrograms/kg) plus glycopyrrolate (14 microgr...ported adverse events (AEs) for the sugammadex
and
neostigmine groups regardless of relationship to the study dru...